Figure 5.

Reduced CSE1L expression correlated with decreased metastasis of B16-F10 cells to the colorectal tract in C57BL/6 mice. A: Expression levels of CSE1L in B16-EV and B16-anti-CSE1L cells were analyzed by immunoblotting with anti-CSE1L antibodies. Levels of β-actin were assayed with anti-β-actin antibodies as the control. B: Reduced CSE1L expression correlated with decreased tumor cell metastasis to the colorectal tract. *P = 0.041 compared with the number of metastases for mice injected with B16-EV control cells. The upper photograph is representative of tumors in the colorectal tract (arrowheads) and lungs (arrows). C: Reduced CSE1L expression decreased mortality of C57BL/6 mice injected with B16-F10 cells. *P = 0.022 compared with mortality of mice injected with B16-EV cells. There were three experimental groups, with each group including 11 mice injected with B16-EV cells and 11 mice injected with B16-anti-CSE1L cells. A total of 66 mice were used. Metastatic tumors in the colorectal tract were counted 25 days after injection. Eleven mice injected with B16-EV cells and six mice injected with B16-anti-CSE1L cells died 3 weeks after injection. Six mice (three injected with B16-EV cells and three injected with B16-anti-CSE1L cells) did not develop tumors. These mice, as well as the mice that died 3 weeks after injection, were excluded from calculations of tumor metastasis.